Clinical trial · Interventional
Effect of Dexmedetomidine on Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Surgery
Effect of Dexmedetomidine on Intraoperative Neuroendocrine Stress Response and Early Postoperative Quality of Recovery in Non-functioning Pituitary Adenoma Patients Undergoing Endoscopic Transsphenoidal Tumor Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In multiple previous studies that have explored the use of dexmedetomidine in transsphenoidal tumor resection surgery, dexmedetomidine showed many beneficial effects like reducing the requirement of analgesics and anesthetics, improving hemodynamic stability and decreasing the emergence time, extubation time and visual analog scale at emergence. Therefore, the investigators hypothesized that dexmedetomidine would decrease neuroendocrine stress response and improve the quality of postoperative recovery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-functioning Pituitary Adenoma | Non-Functioning Pituitary Neuroendocrine Tumor | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Dexmedetomidine | Drug | — | UNRESOLVED |
| normal saline | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Dexmedetomidine group
- description
- After the induction of anesthesia, the dexmedetomidine group received intravenous dexmedetomidine at a loading dose of 1µg/kg for 10 min, followed by a maintenance dose of 0.5µg/kg/h until the end of surgery.
- interventionNames
- Drug: Dexmedetomidine
- type
- PLACEBO_COMPARATOR
- label
- Control group
- description
- After the induction of anesthesia, the control group received intravenous normal saline at the same loading volume for 10 min, followed by the same volume until the end of surgery.
- interventionNames
- Drug: normal saline
Primary outcomes (1)
- measure
- Quality of recovery-15 (QoR-15) score
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Non-functioning patients undergoing endoscopic transsphenoidal tumor surgery under general anesthesia Exclusion Criteria: * Patients who do not agree to participate in the study * Patients with contraindication to dexmedetomidine * Patients with previous history of endoscopic transsphenoidal tumor surgery * Patients who take anticoagulants or have bleeding disorder * Patients with conduction block or cardiovascular disease * Patients with psychiatric disease such as dementia, delirium * Patients have difficulty filling out the QoR-15 questionnaire * Pregnant or lactating women * Patients who have allergies to propofol, remifentanil, fentanyl or rocuronium * Patients with myasthenia gravis or myasthenic syndrome
References
Publications (0)
Data not yet available